Pediatrix Medical reports Q2 adjusted EPS 53c, consensus 42c

Reports Q2 revenue $469M, consensus $464.37M. “Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management,” said Mark Ordan, Chief Executive Officer of Pediatrix Medical (MD) Group. “These results led us to raise our full year 2025 Adjusted EBITDA outlook from a range of $220 million to $240 million to a range of $245 million to $255 million. While we remain cautious in this turbulent period for healthcare and hospital and health systems in particular, we believe the financial flexibility we have built provides both safety and opportunity.”